Created with Sketch.
35 minutes | 13 days ago
STAR Trial with Ji-Hong Liu
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Ji-Hong Liu to discuss the STAR Trial. Dr. Liu is a Professor in the Department of Gynecologic Oncology at Sun Yat-sen University Cancer Center. He is also President-elect of the Gynecologic Oncology Committee of China Anti-Cancer Association. Highlights: - In post-surgery treatment setting, adjuvant sequential chemoradiation was associated with improved disease-free survival compared with radiation alone or concurrent chemoradiation, and was well tolerated. - Sequential chemoradiation also decreased the risk of death compared with radiation alone. - Neither disease-free survival nor cancer death risk was different between patients treated with concurrent chemoradiation or radiation alone. - The detailed QOL results in comparisons between three arms will be orally presented at the annual meeting of SGO 2021 in March. - In conclusion, sequential chemoradiation (SCRT) after radical surgery resulted in a better disease-free survival and lower risk of cancer death for cervical cancer patients with adverse pathological factor, and could be an optimal adjuvant treatment in this setting.
12 minutes | 13 days ago
Reviewing the February Issue with Enrique Chacon (Spanish Version)
In this episode of the IJGC Podcast, Editorial Fellow Enrique Chacon discusses the contents of the February issue in Spanish.
15 minutes | 13 days ago
Reviewing the February Issue with Nicolò Bizzarri (Italian Version)
In this episode of the IJGC Podcast, Editorial Fellow Nicolò Bizzarri discusses the contents of the February issue in Italian.
13 minutes | 13 days ago
Reviewing the February Issue with Alex Mutombo (French Version)
In this episode of the IJGC Podcast, Editorial Fellow Alex Mutombo discusses the contents of the February issue in French.
12 minutes | 13 days ago
Reviewing the February Issue with Irina Tsibulak (Russian Version)
In this episode of the IJGC Podcast, the Editorial Fellow Irina Tsibulak discusses the contents of the February issue in Russian.
11 minutes | 19 days ago
Reviewing the February Issue with Anna Collins and Irina Tsibulak (English Version)
In this episode of the IJGC Podcast, Editorial Fellows Anna Collins and Irina Tsibulak discuss the contents of the February issue.
20 minutes | 20 days ago
Physical Activity in Ovarian Cancer with Tamara Jones
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Tamara Jones to discuss physical activity in ovarian cancer. Dr. Jones is an Accredited Exercise Physiologist and PhD Candidate at Griffith University in Brisbane, Australia. Her research focus is on physical activity and exercise for people with cancer, in particular women with ovarian cancer, and the potentially positive impacts that physical activity and exercise may have on health outcomes.
19 minutes | a month ago
Reviewing the January Issue with Florencia Noll (Spanish Version)
In this episode of the IJGC Podcast, Florencia Noll discusses the contents of the January issue of IJGC in Spanish.
21 minutes | a month ago
Asbestos and Ovarian Cancer with Brian Slomovitz
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Brian Slomovitz to discuss asbestos and ovarian cancer. Dr. Slomovitzs is a Gynecologic Oncologist at Broward Health and Professor of Obstetrics and Gynecology at the Wertheim College of Medicine at Florida International University. He is an internationally recognized leader in gynecologic oncology clinical trials, specifically in immunotherapy and novel biomarker therapeutics. He also is a leader in sentinel lymph node detection for gynecologic malignancies. Highlights a. Asbestos comprises a family of small silicate fibers that are found in nature. b. Asbestos is known to cause different types of cancer. c. The causal association between asbestos and ovarian cancer is weak and inconsistent d. Peritoneal mesothelioma is histologically similar to ovarian cancer and pathologic confirmation of diagnosis is required before causal assumptions are made
26 minutes | a month ago
Ovarian Sex Cord Stromal Tumors with Mona El-Bahrawy
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Mona El-Bahrawyto discuss ovarian sex cord stromal tumors. Dr. El-Bahrawy is the lead author of “Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management" (https://ijgc.bmj.com/content/early/2021/01/07/ijgc-2020-002018), which is the Lead Article of IJGC’s February 2021 issue. Dr. El-Bahrawy is Professor of Practice in Histopathology at Imperial College London, United Kingdom, and Professor of Pathology at the University of Alexandria, Egypt, and President of the Egyptian Committee for Pathology Training. She specializes in Gynaecological Surgical Pathology with special interest in Gynaecological Tumour Pathology. Highlights: - Ovarian sex cord stromal tumours are rare tumours that include benign and malignant variants. - They are broadly classified into three categories, which include pure stromal tumors, pure sex cord tumors and mixed sex cord stromal tumors. - Some tumor types harbor hallmark mutations, such as FOXL-2 mutations detected in the majority of adult granulosa cell tumors. - Surgery is the main treatment modality for sex cord stromal tumors with some role for chemotherapy and hormonal therapy in advanced and recurrent tumors. - There is potential for the identification of therapeutic targets and development of targeted therapy for these tumors.
14 minutes | a month ago
Reviewing the January Issue with Sadie Jones and Navya Nair (English Version)
In this issue of the IJGC Podcast, Editorial Fellows Sadie Jones and Navya Nair discuss the contents of the January issue of IJGC.
28 minutes | 2 months ago
Role of Trastuzumab in Uterine Papillary Serous Tumors with Amanda Fader
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Amanda Fader to discuss the role of trastuzumab in uterine papillary serous tumors. Dr. Fader is an Associate Professor of Gynecology and Obstetrics, Vice Chair of Gynecologic Surgical Operations and Director of the Center for Rare Gynecologic Cancers at Johns Hopkins School of Medicine. She is recognized internationally as a rare uterine and ovarian cancer expert and is an active member of NRG Oncology and helps develop and co-lead innovative gynecologic cancer clinical trials. Highlights: • Uterine serous carcinoma (USC) is a biologically aggressive endometrial cancer subtype that accounts for a disproportionately high rate of endometrial cancer-related deaths. • 25-30% of women with both early and advanced stage USC will have HER2 positive tumors. • Molecularly-based therapeutic approaches in USC are increasing. • Trastuzumab, an anti-HER2 therapy, in combination with platinum/taxane-based chemotherapy improves survival outcomes for women with HER2 positive USC. • A randomized, Phase III cooperative group study is planned to study additional anti-HER2 therapies in women with all stages of USC.
35 minutes | 2 months ago
100th Podcast: Conversaciones con el Editor-en-Jefe
Para celebrar el podcast número 100 de la revista IJGC, el Comité Editorial propuso entrevistar en español a nuestro Editor-en-Jefe , el Dr. Pedro Ramírez. El Dr. Luis Chiva, Video-Editor de nuestra revista y miembro del consejo de ESGO realizó recientemente esta tarea. En este encuentro tan especial, el Dr. Pedro Ramirez nos cuenta muchos detalles que revelan cuales son los sueños que desearía que se hicieran realidad en un futuro proximo en nuestra revista
25 minutes | 2 months ago
100th Podcast: Conversations with the Editor-in-Chief
In honor of the International Journal of Gynecological Cancer’s 100th podcast, IJGC’s Editor-in-Chief, Dr. Pedro Ramirez, is interviewed by IGCS President and IJGC Editorial Board Member Dr. Robert Coleman to discuss the experiences of the Editor-in-Chief.
30 minutes | 2 months ago
SENTOR Study: SLN in High-Risk Endometrial Cancer with Sarah Ferguson
Dr. Ferguson is a Professor in the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Toronto and a member of the Division of Gynecologic Oncology at University Health Network/Sinai Health Systems. She is the Director of Research for the Division of Gynecologic Oncology at Princess Margaret Cancer. Dr. Ferguson completed her residency in Obstetrics and Gynecology at University of Toronto and a fellowship at Memorial Sloan-Kettering Cancer Centre in Gynecologic Oncology. Current research program includes prospective surgical trials in cervical and endometrial cancer, evaluation of patient reported outcomes and molecular characterization of endometrial cancer. Highlights: + Diagnostic accuracy of SLN technique is excellent in high grade endometrial cancer – high sensitivity (low false negative rate), high NPV , DR and bilaterality rate + Based on this is a viable option to surgical staging in this population (clinical stage 1, high grade endometrial cancer) + High proportion (26%) of node positive would be missed if SLN technique was not performed
43 minutes | 2 months ago
ESGO-ESTRO-ESP Endometrial Cancer Guidelines with Nicole Concin
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Nicole Concin to discuss the ESGO-ESTRO-ESP Endometrial Cancer Guidelines (https://ijgc.bmj.com/content/early/2020/12/18/ijgc-2020-002230)
35 minutes | 2 months ago
Options of Urinary Diversion in Gynecologic Oncology with Carlos Martinez-Gomez
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Carlos Martinez-Gomez to discuss TOPIC. Dr. Martinez-Gomez is an author of the Lead Article for IJGC’s January 2021 issue, “Urinary diversion after pelvic exenteration for gynecologic malignancies” (https://ijgc.bmj.com/content/early/2020/11/22/ijgc-2020-002015). Dr. Martinez-Gomez is a gynecologist oncologist at Institut Universitaire du Cancer de Toulouse, France, from 2016, where he performed the ESGO fellowship program under the supervision of Drs. Gwénaël Ferron and Alejandra Martinez. His areas of interest are immunology of cervical and ovarian neoplasms, advanced ovarian cancer, reconstructive surgery after pelvic exenteration, and surgical teaching. Highlights: • Pelvic exenteration is a demanding surgery requiring mastery of organ removal combined with functional reconstruction • Pelvic exenteration should be performed in high-volume referral institutions by well-trained multidisciplinary teams • Incontinent diversion represents a good option for unfit patients or those refusing the constraints entailed by continent diversions (self-catheterization, postoperative learning, engagement) • Postoperative complications of both types of reconstruction are comparable, but the quality of life issues would seem to support continent diversions in young and fit patients • Continent and non-contingent techniques should be offered to patients, with a final decision based on their preferences
22 minutes | 3 months ago
Reviewing the December Issue with Florencia Noll (Spanish Version)
In this episode of the IJGC Podcast, Florencia Noll discusses the contents of the December issue of IJGC in Spanish.
16 minutes | 3 months ago
Reviewing the December Issue with Sadie Jones and Navya Nair (English Version)
In this issue of the IJGC Podcast, Editorial Fellows Sadie Jones and Navya Nair discuss the contents of the December issue of IJGC.
48 minutes | 3 months ago
Best of 2020: Updates on Role of HIPEC in Ovarian Cancer with Oliver Zivanovic
In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Oliver Zivanovic to discuss updates on role of HIPEC in ovarian cancer. Dr. Zivanovic is a Gynecologic Cancer Surgeon at Memorial Sloan Kettering Cancer Center, with the goal to advance the early detection and treatment of women with gynecologic cancers. His special interests include the treatment of patients with advanced stage ovarian cancer and electronic patient-reported symptom monitoring after cancer surgery.
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2020